COLLECTFIRST(TM) SYSTEM RECEIVES FDA MARKET APPROVAL.

BRAINTREE, MA--(BUSINESS WIRE)--July 24, 1995 -- Haemonetics Corporation (NYSE: HAE) announced that the CollectFirst(TM) system has received Food and Drug Administration 510K substantial equivalence.

The CollectFirst(TM) system is the newest product offering from Haemonetics in the area of surgical autotransfusion. The CollectFirst(TM) system, approved for both intraoperative and postoperative autotransfusion, allows continuous collection, filtration, and reinfusion of salvaged blood. This system offers versatility to the physician through its unique ability to be used either for direct reinfusion, or with the Haemonetics(R) Cell Saver(R) system for washing of the collected red blood cells. The CollectFirst(TM) system provides the physician the true option to collect the salvaged blood first and then determine the appropriate choice of care for the patient.

Autotransfusion is the practice of a patient having their own red blood cells collected and returned during or after surgery.

John F. White, Chairman, CEO and President of Haemonetics said, "The CollectFirst(TM) system expands our surgical product offerings both in the cardiovascular suite and more importantly for non- open heart cases, particularly in orthopedics. It provides physicians with options in intraoperative and postoperative autologous blood management. Sales of these systems will begin this quarter and are expected to be more significant as the fiscal year continues."

Haemonetics is engaged in the design, manufacture and worldwide marketing of automated systems for the extracorporeal processing of blood. The company's systems address three important medical markets around which the company has focused its business: surgical blood salvage, blood component therapy and automated plasma collection.

CONTACT: Haemonetics, Braintree

Stephen P. Oliver, [phone]